Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yuanbin Chen (NPI 1467627653)

Field	Value
Entity Type	Individual
Organization	Yuanbin Chen
Address	1400 S Orange Ave
City	Orlando
State	FL
ZIP	32806
Taxonomy	Medical Oncology Physician
NPI Enumerated	April 28, 2008

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider is a medical oncology physician in Orlando, FL with long-established Medicare participation — the NPI was enumerated 2008-04-28 (~18 years ago), indicating nearly two decades of billing history and likely sustained practice operations. That tenure supports interpretation of the reported billing mix as a stable clinical pattern rather than a transient or new specialty shift.

Medicare is the sole payer in the dataset for this provider: total Medicare revenue is $2.7M while there is no Medicaid billing on file, so the practice is effectively single-payer in the available claims universe and any Medicaid-related market exposure or risk is not observable.

Revenue is highly concentrated in a small set of high-cost oncology drugs and immunotherapies: the precomputed top three Medicare codes by revenue account for 74.2% of total Medicare revenue, signifying that a few injectable oncology agents drive most of the practice’s Medicare income. Clinically, that concentration is consistent with an infusion-based oncology practice focused on systemic anticancer therapy rather than primarily office-based E/M visits.

The top individual revenue driver is J9299 (nivolumab 1 mg), which generated $779.8K and represents 29.4% of the provider’s Medicare revenue; the provider ranks #59 of 505 nationally for this code (88th percentile), indicating a solid but not dominant national position and typical volume relative to peers for this drug. Similarly, J9228 (ipilimumab 1 mg) produced $637.5K (24.0% of Medicare revenue) and ranks #6 of 12 nationally (55th percentile), a modest national presence with typical volume language in the benchmark notes.

A third high-revenue oncology drug, J9271 (pembrolizumab 1 mg), contributed $551.6K (20.8% of Medicare revenue) and the provider ranks #865 of 1841 nationally (53th percentile), again described as a typical, unremarkable volume. Together these three immuno-oncology agents form the core of the practice’s billings and indicate ongoing delivery of checkpoint inhibitor therapies.

Beyond drug administration, procedural and E/M activity is present but comparatively small: chemotherapy administration add-on and infusion codes such as 96413 ($56.4K, 2.1% of Medicare revenue) rank notably above typical national volume (95th percentile), while standard E/M codes like 99214 and 99213 together account for only ~1.6% of Medicare revenue, suggesting the practice emphasizes drug delivery/infusions over high-volume outpatient visit billing.

There are select areas of unusually high procedural volume relative to national peers: 96413 is explicitly flagged as "notably above typical national volume" (95th percentile), suggesting the provider administers chemotherapy infusions at a higher-than-typical rate for peers. Conversely, many other codes (multiple J-codes and E/M codes) are described as "typical, unremarkable volume," indicating that aside from certain infusion administration counts, the provider’s mix aligns with common oncology practice patterns.

Lab and ancillary services are supportive but not major revenue sources: panels and common lab codes (80053, 84443, 85025) each contribute small amounts (<0.3% of Medicare revenue) and generally rank high in percentiles (around the 90th percentile), implying that while labs are frequently ordered, they are a standard complement to the infusion-centered care model rather than a primary revenue stream.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

60 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	32,490	$20	$779.8K
J9228	Injection, ipilimumab, 1 mg	4,900	$130	$637.5K
J9271	Injection, pembrolizumab, 1 mg	12,830	$40	$551.6K
J9304	Injection, pemetrexed (pemfexy), 10 mg	5,160	$60	$314.6K
J1930	Injection, lanreotide, 1 mg	3,840	$40	$165.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	610	$90	$56.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	290	$90	$26.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	260	$60	$15.8K
M0010	Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services	170	$80	$12.9K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	80	$130	$9.9K

Showing 1–10 of 60

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 60 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Yuanbin Chen — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

60 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	210	16,100	$40	$802.7K
J9299	1	70	15,580	$20	$423.9K
J9304	1	10	2,660	$60	$147.6K
J3490	18	180	70	$280	$87.5K
96413	3	730	200	$100	$26.1K
99214	2,073	32,760	140	$90	$25K
80053	25	1,430	170	$10	$21.3K
84443	23	1,210	130	$20	$20.9K
99233	1,662	9,970	100	$90	$20.1K
82024	1	30	60	$40	$14.4K

Showing 1–10 of 60

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yuanbin Chen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Orlando Health, Inc.	FL	General Acute Care Hospital	$0	$105.5M
Cancer & Hematology Centers Of Western Mi, P.C.	MI	Specialist	$0	$59.5M
Orlando Health Medical Group Inc	FL	Internal Medicine Physician	$0	$57.6M
Spectrum Health United	MI	General Acute Care Hospital	$0	$20.9M
South Lake Hospital, Inc.	FL	General Acute Care Hospital	$0	$16.9M
Orlando Health Central, Inc.	FL	General Acute Care Hospital	$0	$12.5M
Orlando Physicians Network Inc	FL	Internal Medicine Physician	$0	$9.4M
Spectrum Health United	MI	Rural Health Clinic/Center	$0	$6.6M
Amarilis Torres	FL	Rheumatology Physician	$1.7M	$0
Adli Yakan	MI	Medical Oncology Physician	$1.7M	$0

Nearby Providers

Other providers in the same ZIP code as Yuanbin Chen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Emergency Physicians Of Central Florida LLP	FL	Emergency Medicine Physician	$0	$50M
Nemours Children's Health, Downtown Orlando, Specialty Care	FL	Multi-Specialty Clinic/Center	$0	$44.4M
Dva Renal Healthcare Inc	FL	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$14.5M
Elia Mavrofrides	FL	Ophthalmology Physician	$6.2M	$240
Samuel Houston	FL	Ophthalmology Physician	$4.2M	$39.3K
Matthew Cunningham	FL	Ophthalmology Physician	$4M	$1.8K
Eric Feinstein	FL	Ophthalmology Physician	$3.4M	$1.5K
Jaya Kumar	FL	Ophthalmology Physician	$3.4M	$3K
John Randolph	FL	Ophthalmology Physician	$3M	$0
Gokul Kumar	FL	Ophthalmology Physician	$3M	$0

Yuanbin Chen — Billing Profile & Reimbursement Data

Sign up for Yuanbin Chen — Billing Profile & Reimbursement Data policy alerts

Yuanbin Chen — Billing Profile & Reimbursement Data

Sign up for Yuanbin Chen — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References